title: [Use of recombinant alpha2-interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia].
abstract: The authors present results of chronic myeloid leukemia (CML) treatment with recombinant and leukocytic interferon in monotherapy and in combination with myelosan. The best responses (72% of complete hematological remissions) were obtained in patients pretreated with myelosan (one course of 1-1.5 months) in combination with natural antioxidants.
authors.forename: V I
authors.initials: VI
authors.lastname: Petukhov
authors.forename: I
authors.initials: I
authors.lastname: Strozha
authors.forename: D K
authors.initials: DK
authors.lastname: Bondare
authors.forename: G Ia
authors.initials: GIa
authors.lastname: Feldmane
authors.forename: M
authors.initials: M
authors.lastname: Mauritsas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan
vernacular_title: Primenenie rekombinantnogo alpha2-interferona v sochetanii s mielosanom dlia lecheniia bol'nykh khronicheskim mieloleĭkozom.